|
[1]PUROHIT T, CAPPELL MS, et al.Primary biliary cirrhosis:pathophysiology, clinical presentation and therapy[J].World JHepatol, 2015, 7 (7) :926-941.
|
|
[2]HIRSCHFIELD GM, SIMINOVITCH KA, et al.Genetic in PBC:what do the“risk genes”teach us?[J].Clinic Rev Allerg Immunol, 2015, 48 (2-3) :176-181.
|
|
[3]WONG GL, HUI AY, WONG VW, et al.A retrospective study on clinical features and prognostic factors of biopsy-proven primary biliary cirrhosis in Chinese patients[J].Am J Gastroenterol, 2005, 100 (10) :2205-2211.
|
|
[4]FLORES A, MAYO MJ.Primary biliary cirrhosis in 2014[J].Curr Opin Gastroenterol, 2014, 30 (3) :245-252.
|
|
[5]TRYNKA G, HUNT KA, BOCKETT NA, et al.Dense genotyping identifies and localizes multiple common and rare variant association signals in celiac disease[J].Nat Genet, 2011, 43 (12) :1193-1201.
|
|
[6]SELMI C, MAYO M J, BACH N, et al.Primary biliary cirrhosis in monozygotic and dizygotic twins:genetics, epigenetics, and environment[J].Gastroenterology, 2004, 127 (2) :485-492.
|
|
[7]CAREY EJ, ALI AH, LINDOR KD.Primary biliary cirrhosis[J].Lancet, 2015, 386 (10003) :1565-1576.
|
|
[8]HIRSCHFIELD GM, INVERNIZZI P.Progress in the genetics of primary biliary cirrhosis[J].Semin Liver Dis, 2011, 31 (2) :147-156.
|
|
[9]HUANG YQ.Recent advances in the diagnosis and treatment of primary biliary cholangitis[J].World J Hepatol, 2016, 8 (33) :1419-1441.
|
|
[10]JOSHITA S, UMEMURA T, TANAKA E, et al.Genetic contribution to the pathogenesis of primary biliary cholangitis[J].J Immunol Res, 2017, 2017:3073504.
|
|
[11]DONALDSON PT, BARAGIOTTA A, HENEGHAN MA, et al.HLA class II alleles, genotypes, haplotypes, and amino acids in primary biliary cirrhosis:a large-scale study[J].Hepatology, 2006, 44 (3) :667-674.
|
|
[12]MULLARKEY ME, STEVENS AM, MCDONNELL WM, et al.Human leukocyte antigen class II alleles in Caucasian women with primary biliary cirrhosis[J].Tissue Antigens, 2005, 65 (2) :199-205.
|
|
[13]ONISHI S, SAKAMAKI T, MAEDA T, et al.DNA typing of HLAclass II genes;DRB1*0803 increases the susceptibility of Japanese to primary biliary cirrhosis[J].J Hepatol, 1994, 21 (6) :1053-1060.
|
|
[14]LIU HY, DENG AM, ZHANG J, et al.Analysis of HLA alleles polymorphism in Chinese patients with primary biliary cirrhosis[J].Chin J Hepatal, 2005, 13 (6) :410-413. (in Chinese) 刘海英, 邓安梅, 张建, 等.原发性胆汁性肝硬化患者人类白细胞抗原等位基因多态性分析[J].中华肝脏病杂志, 2005, 13 (6) :410-413.
|
|
[15]JIANG XH, ZHONG RQ, FANG XY, et al.Relationship between alleles of HLA-DRB and HLA-DQB1 and Chinese patients with primary biliary cirrhosis[J].Chin J Hepatol, 2004, 12 (7) :436. (in Chinese) 姜小华, 仲人前, 方晓云, 等.原发性胆汁性肝硬化与HLA-DRB1、DQB1等位基因的相关性研究[J].中华肝脏病杂志, 2004, 12 (7) :436.
|
|
[16]LI M, ZHENG H, TIAN QB, et al.HLA-DR polymorphism and primary biliary cirrhosis:evidence from a meta-analysis[J].Arch Med Res, 2014, 45 (3) :270-279.
|
|
[17]UMEMURA T, JOSHITA S, ICHIJO T, et al.Human leukocyte antigen class II molecules confer both susceptibility and progression in Japanese patients with primary biliary cirrhosis[J].Hepatology, 2012, 55 (2) :506-511.
|
|
[18]KUMAGI T, ABE M, IKEDA Y, et al.Infection as a risk factor in the pathogenesis of primary biliary cirrhosis:pros and cons[J].Dis Markers, 2010, 29 (6) :313-321.
|
|
[19]QIU F, TANG R, ZUO X, et al.A genome-wide association study identifies six novel risk loci for primary biliary cholangitis[J].Nat Commun, 2017, 8:14828.
|
|
[20]CORDELL HJ, HAN Y, MELLS GF, et al.International genomewide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways[J].Nat Commun, 2015, 6:8019.
|
|
[21]NAKAMURA M, NISHIDA N, KAWASHIMA M, et al.Genomewide association study identifies TNFSF15 and POU2AF1 as susceptibility loci for primary biliary cirrhosis in the Japanese population[J].Am J Hum Genet, 2012, 91 (4) :721-728.
|
|
[22]LIU JZ, ALMARRI MA, GAFFNEY DJ, et al.Dense fine-mapping study identifies new susceptibility loci for primary biliary cirrhosis[J].Nat Genet, 2012, 44 (10) :1137-1141.
|
|
[23]JURAN BD, HIRSCHFIELD GM, INVERNIZZI P, et al.Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants[J].Hum Mol Genet, 2012, 21 (23) :5209-5221.
|
|
[24]MELLS GF, FLOYD JA, MORLEY KI, et al.Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis[J].Nat Genet, 2011, 43 (4) :329-332.
|
|
[25]LIU X, INVERNIZZI P, LU Y, et al.Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis[J].Nat Genet, 2010, 42 (8) :658-660.
|
|
[26]HIRSCHFIELD GM, LIU X, HAN Y, et al.Variants at IRF5-TNPO3, 17q12-21 and MMEL1 are associated with primary biliary cirrhosis[J].Nat Genet, 2010, 42 (8) :655-657.
|
|
[27]HIRSCHFIELD GM, LIU X, XU C, et al.Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants[J].N Engl JMed, 2009, 360 (24) :2544-2555.
|
|
[28]van WANROOIJ RL, ZWIERS A, KRAAL G, et al.Genetic variations in interleukin-12 related genes in immune-mediated diseases[J].J Autoimmun, 2012, 39 (4) :359-368.
|
|
[29]YANG CY, MA X, TSUNEYAMA K, et al.IL-12/Th1 and IL-23/Th17 biliary microenvironment in primary biliary cirrhosis:implications for therapy[J].Hepatology, 2014, 59 (5) :1944-1953.
|
|
[30]HIRSCHFIELD GM, CHAPMAN RW, KARLSEN TH, et al.The genetics of complex cholestatic disorders[J].Gastroenterology, 2013, 144 (7) :1357-1374.
|
|
[31]GULAMHUSEIN AF, JURAN BD, LAZARIDIS KN.Genomewide association studies in primary biliary cirrhosis[J].Semin Liver Dis, 2015, 35 (4) :392-401.
|
|
[32]PUIMEGE L, LIBERT C, van HAUWERMEIREN F.Regulation and dysregulation of tumor necrosis factor receptor-1[J].Cytokine Growth Factor Rev, 2014, 25 (3) :285-300.
|
|
[33]KITAMURA K, NAKAMOTO Y, AKIYAMA M, et al.Pathogenic roles of tumor necrosis factor receptor p55-mediated signals in dimethylnitrosamine-induced murine liver fibrosis[J].Lab Invest, 2002, 82 (5) :571-583.
|
|
[34]CHIKUMA S.CTLA-4, an essential immune-checkpoint for T-cell activation[J].Curr Top Microbiol Immunol, 2017.[Epub ahead of print]
|
|
[35]WOLF A, BEUERLEIN K, ECKART C, et al.Identification and functional characterization of novel phosphorylation sites in TAK1-binding protein (TAB) 1[J].PLo S One, 2011, 6 (12) :e29256.
|
|
[36]ELSHARKAWY AM, OAKLEY F, LIN F, et al.The NF-kappa Bp50:p50:HDAC-1 repressor complex orchestrates transcriptional inhibition of multiple pro-inflammatory genes[J].J Hepatol, 2010, 53 (3) :519-527.
|
|
[37]BIANCHI I, CARBONE M, LLEO A, et al.Genetics and epigenetics of primary biliary cirrhosis[J].Semin Liver Dis, 2014, 34 (3) :255-264.
|
|
[38]SELMI C, CAVACIOCCHI F, LLEO A, et al.Genome-wide analysis of DNA methylation, copy number variation, and gene expression in monozygotic twins discordant for primary biliary cirrhosis[J].Front Immunol, 2014, 5:128.
|
|
[39]HU Z, HUANG Y, LIU Y, et al.beta-Arrestin 1 modulates functions of autoimmune T cells from primary biliary cirrhosis patients[J].J Clin Immunol, 2011, 31 (3) :346-355.
|
|
[40]NINOMIYA M, KONDO Y, FUNAYAMA R, et al.Distinct microRNAs expression profile in primary biliary cirrhosis and evaluation of miR 505-3p and miR197-3p as novel biomarkers[J].PLo S One, 2013, 8 (6) :e66086.
|
|
[41]WEBB GJ, SIMINOVITCH KA, HIRSCHFIELD GM.The immunogenetics of primary biliary cirrhosis:a comprehensive review[J].JAutoimmun, 2015, 64:42-52.
|
|
[42]CIRULLI ET, GOLDSTEIN DB.Uncovering the roles of rare variants in common disease through whole-genome sequencing[J].Nat Rev Genet, 2010, 11 (6) :415-425.
|
|
[43]SUN L, ZHANG X, HE L.GWAS promotes precision medicine in China[J].J Genet Genomics, 2016, 43 (8) :477-479.
|
|
[44]DONG M, LI J, TANG R, et al.Multiple genetic variants associated with primary biliary cirrhosis in a Han Chinese population[J].Clin Rev Allergy Immunol, 2015, 48 (2-3) :316-321.
|
|
[45]LAMMERS WJ, HIRSCHFIELD GM, CORPECHOT C, et al.Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy[J].Gastroenterology, 2015, 149 (7) :1804-1812.
|
|
[46]SAMUR S, KLEBANOFF M, BANKEN R, et al.Long-term clinical impact and cost-effectiveness of obeticholic acid for the treatment of primary biliary cholangitis[J].Hepatology, 2017, 65 (3) :920-928.
|
|
[47]HIRSCHFIELD GM, MASON A, LUKETIC V, et al.Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid[J].Gastroenterology, 2015, 148 (4) :751-761.
|
|
[48] NEVENS F, ANDREONE P, MAZZELLA G, et al.A placebocontrolled trial of obeticholic acid in primary biliary cholangitis[J].N Engl J Med, 2016, 375 (7) :631-643.
|
|
[49]HEGADE VS, KHANNA A, WALKER LJ, et al.Long-term fenofibrate treatment in primary biliary cholangitis improves biochemistry but not the UK-PBC risk score[J].Dig Dis Sci, 2016, 61 (10) :3037-3044.
|
|
[50]MOUSA H, LLEO A, INVERNIZZI P, et al.Advanced in pharmacotherapy for primary biliary cirrhosis[J].Expert Opin Pharmacother, 2015, 16 (5) :633-643.
|
|
[51]EGAWA H, SAKISAKA S, TERAMUKAI S, et al.Long-term outcomes of living-donor liver transplantation for primary biliary cirrhosis:a Japanese multicenter study[J].Am J Transplant, 2016, 16 (4) :1248-1257.
|
|
[52]WEBB CF, BRYANT J, POPOWSKI M, et al.The ARID family transcription factor bright is required for both hematopoietic stem cell and B lineage development[J].Mol Cell Biol, 2011, 31 (5) :1041-1053.
|
|
[53] MYERS RP, SWAIN MG, LEE SS, et al.B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid[J].Am J Gastroenterol, 2013, 108 (6) :933-941.
|
|
[54]DHIRAPONG A, LLEO A, YANG GX, et al.B cell depletion therapy exacerbates murine primary biliary cirrhosis[J].Hepatology, 2011, 53 (2) :527-535.
|
|
[55]HIRSCHFIELD GM, GERSHWIN ME, STRAUSS R, et al.Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid:a proof-of-concept study[J].Hepatology, 2016, 64 (1) :189-199.
|
|
[56]TACKE F, LUEDDE T, TRAUTWEIN C.Inflammatory pathways in liver homeostasis and liver injury[J].Clin Rev Allergy Immunol, 2009, 36 (1) :4-12.
|
|
[57]XIAO L, JIA L, ZHANG Y, et al.Human IL-21+IFN-gamma+CD4+T cells in nasal polyps are regulated by IL-12[J].Sci Rep, 2015, 5:12781.
|
|
[58]MEAGHER C, BEILKE J, ARREAZA G, et al.Neutralization of interleukin-16 protects nonobese diabetic mice from autoimmune type 1 diabetes by a CCL4-dependent mechanism[J].Diabetes, 2010, 59 (11) :2862-2871.
|
DownLoad: